Modulation of ptpra to treat arthritis
AssigneesLa Jolla Institute for Allergy and Immunology, The Regents of the University of California
InventorsNunzio Bottini, Gary Firestein, Stephanie Stanford
Life of this patent
Estimating the term…
Abstract
Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (PT-PRA) antagonist.
Claims54
A method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to said subject an effective amount of a protein tyrosine phosphatase receptor type A (PTPRA) antagonist, thereby treating an autoimmune disease in said subject.
A method of identifying a PTPRA antagonist, the method comprising:
- (i) contacting a test agent with a sarcoma tyrosine kinase (SRC)-expressing cell in vitro, thereby forming a contacted cell;
- and
- (ii) determining in said contacted cell a level of SRC Tyr527 phosphorylation, wherein an increased level of SRC Tyr527 phosphorylation indicates said test agent is a PTPRA antagonist, thereby identifying a PTPRA antagonist.
A method of identifying a PTPRA antagonist, the method comprising:
- (i) contacting a test agent with a focal adhesion kinase (FAK)-expressing cell in vitro, thereby forming a contacted cell;
- and
- (ii) determining in said contacted cell a level of FAK Tyr397 phosphorylation, wherein a decreased level of FAK Tyr397 phosphorylation indicates said test agent is a PTPRA antagonist, thereby identifying a PTPRA antagonist.
The method of one of claims 21-24, wherein said cell is derived from a subject having or being at risk for developing an autoimmune disease.
A method of inhibiting PTPRA protein activity in a cell, the method comprising contacting a cell with an effective amount of a PTPRA antagonist thereby inhibiting PTPRA protein activity in said cell.
A pharmaceutical composition comprising a PTPRA antagonist and a pharmaceutically acceptable recipient.
A method of decreasing inflammation in a synovium of a subject in need thereof, the method comprising administering to the subject an effective amount of a PTPRA antagonist, wherein said PTPRA antagonist is an anti-PTPRA antibody, an anti-PTPRA inhibitory nucleic acid, peptide, or a small molecule.
A method of inhibiting expression of a growth factor in a fibroblast-like synoviocyte, the method comprising contacting said fibroblast-like synoviocyte with an effective amount of a PTPRA antagonist, thereby inhibiting expression of a growth factor in a fibroblast-like synoviocyte,
A method of inhibiting expression of inflammatory cytokines in a fibroblast-like synoviocyte, the method comprising contacting said fibroblast-like synoviocyte with an effective amount of a PTPRA antagonist, thereby inhibiting expression of inflammatory cytokines in a fibroblast-like synoviocyte.
Dependencies are inferred from the claim text.